Abstract
Over the last two decades proteins have become increasingly important in human therapy and diagnosis. Engineering therapeutic proteins through improving their biological activity and stability has been a major interest in our group. In this mini-review we summarize our research on three proteins with pharmaceutical potential – serine protease inhibitor from squash seeds (CMTI), bovine pancreatic trypsin inhibitor (BPTI), and human fibroblast growth factor 1 (FGF1). To improve the functional properties of these proteins we used multiple techniques such as homology approach, rational design, total chemical synthesis, site-directed mutagenesis and phage display. The physicochemical properties of the obtained protein variants were evaluated using protein crystallography, spectroscopic techniques, enzymatic assays, stability measurements as well as numerous biological tests.
Keywords: Protein engineering, protein therapeutics, protease inhibitors, squash inhibitors, BPTI, FGF1, protein stability, human therapy and diagnosis, homology approach, numerous biological tests, Hageman factor, pharmacological properties, antimicrobial peptides, heparan sulfate proteoglycans (HSPGs), heparans (HS)
Current Pharmaceutical Biotechnology
Title: Tailoring Small Proteins Towards Biomedical Applications
Volume: 12 Issue: 11
Author(s): Malgorzata Zakrzewska, Anna Szlachcic and Jacek Otlewski
Affiliation:
Keywords: Protein engineering, protein therapeutics, protease inhibitors, squash inhibitors, BPTI, FGF1, protein stability, human therapy and diagnosis, homology approach, numerous biological tests, Hageman factor, pharmacological properties, antimicrobial peptides, heparan sulfate proteoglycans (HSPGs), heparans (HS)
Abstract: Over the last two decades proteins have become increasingly important in human therapy and diagnosis. Engineering therapeutic proteins through improving their biological activity and stability has been a major interest in our group. In this mini-review we summarize our research on three proteins with pharmaceutical potential – serine protease inhibitor from squash seeds (CMTI), bovine pancreatic trypsin inhibitor (BPTI), and human fibroblast growth factor 1 (FGF1). To improve the functional properties of these proteins we used multiple techniques such as homology approach, rational design, total chemical synthesis, site-directed mutagenesis and phage display. The physicochemical properties of the obtained protein variants were evaluated using protein crystallography, spectroscopic techniques, enzymatic assays, stability measurements as well as numerous biological tests.
Export Options
About this article
Cite this article as:
Zakrzewska Malgorzata, Szlachcic Anna and Otlewski Jacek, Tailoring Small Proteins Towards Biomedical Applications, Current Pharmaceutical Biotechnology 2011; 12 (11) . https://dx.doi.org/10.2174/138920111798376905
DOI https://dx.doi.org/10.2174/138920111798376905 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Hashimotos Thyroiditis: From Genes to the Disease
Current Genomics Role of Lipoxins and Resolvins as Anti-Inflammatory and Proresolving Mediators in Colon Cancer
Current Molecular Medicine Endothelial Cells in Inflammation and Angiogenesis
Current Drug Targets - Inflammation & Allergy Synthesis of 4-Phenylthieno[2,3-e][1,2,4]triazolo[4,3-a]pyrimidine-5(4H)-one Derivatives and Evaluation of Their Anti-inflammatory Activity
Letters in Drug Design & Discovery Application of Decoy Oligodeoxynucleotides-Based Approach to Renal Diseases
Current Drug Targets Molecular Biomarkers in Schizophrenia – Implications for Clinical Practice
Current Psychiatry Reviews Is it Possible to More Accurately Predict which Drug Candidates will cause Idiosyncratic Drug Reactions
Current Drug Metabolism Diabetes Type 4: A Paradigm Shift in the Understanding of Glaucoma, the Brain Specific Diabetes and the Candidature of Insulin as a Therapeutic Agent
Current Molecular Medicine Dopamine: The Forgotten Felon in Type 2 Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Editorial from Guest Editor [Hot topic: Novel Inflammatory Biomarkers in Diseases (Guest Editor: Yu Chen)]
Inflammation & Allergy - Drug Targets (Discontinued) Dual-Specificity MAP Kinase Phosphatases as Targets of Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry The Need for Physiologically Relevant Peroxisome Proliferator-Activated Receptor-gamma (PPAR-γ) Ligands
Endocrine, Metabolic & Immune Disorders - Drug Targets Second Messenger Modulation: A Novel Target of Future Antidepressants?
Current Medicinal Chemistry Management of Early Stage Chronic Myeloid Leukemia: State-of-the-art Approach and Future Perspectives
Current Cancer Drug Targets Molecular Genetics and Epidemiology of Osteoporosis
Current Pharmacogenomics The Role of Epidermal Growth Factor Receptor in the Management of Gastrointestinal Carcinomas: Present Status and Future Perspectives
Current Pharmaceutical Design Vitamin D and Cancer Mortality: Systematic Review of Prospective Epidemiological Studies
Anti-Cancer Agents in Medicinal Chemistry FOXP3: Required but Not Sufficient. The Role of GARP (LRRC32) as a Safeguard of the Regulatory Phenotype
Current Molecular Medicine Perioperative Management of Antiplatelet-Drugs in Cardiac Surgery
Current Cardiology Reviews A New Approach to the Inflammatory/Autoimmune Diseases
Recent Patents on Anti-Infective Drug Discovery